Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Genor Biopharma Holdings Limited ( (HK:6998) ) has provided an announcement.
Genor Biopharma Holdings Limited reported a significant increase in revenue for the first half of 2025, driven by license and stock purchase agreements, while also reducing its comprehensive loss due to decreased expenses. The company has achieved a light-asset operation, reducing costs and promoting strategic cooperation, including a proposed merger with Edding and the advancement of its drug pipeline, highlighted by the approval of Lerociclib for breast cancer treatment and the initiation of clinical trials for other key products.
More about Genor Biopharma Holdings Limited
Genor Biopharma Holdings Limited operates in the biopharmaceutical industry, focusing on the development and commercialization of innovative drugs. The company is involved in strategic collaborations and is advancing its pipeline of products, including treatments for cancer and autoimmune diseases.
Average Trading Volume: 2,076,172
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.2B
For an in-depth examination of 6998 stock, go to TipRanks’ Overview page.